Researchers have made a major advance in quantum computing with a new device that is nearly 100 times smaller than the ...

OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral ...

A Brazilian study has confirmed that Joseph’s Coat, a plant used for generations in folk medicine, can significantly reduce inflammation and arthritis symptoms in lab tests. Researchers observed less ...

The Phase 1b study is designed to evaluate the safety and tolerability of orally administered balomenib over a 28-day treatment period, followed by a post-treatment observation phase of up to ...

Scientists at the University of Oxford demonstrate an approach to interpreting how materials interact with polarized light, ...

Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, ...

Peptinov today announced the publication of the Phase 1 clinical results for PPV-06, its first-in-class active immunotherapy targeting IL-6, in the peer-reviewed journal Nature Communications. The ...

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in ...

Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for the treatment of metastatic ...

Xenon Pharmaceuticals (XENE) is undervalued given azetukalner's late-stage potential to transform epilepsy and mood disorder ...

KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation ...

The latest update is out from Tiziana Life Sciences ( (TLSA) ).